+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intravenous Iron Drugs Market - Global Forecast 2026-2032- Product Image
Intravenous Iron Drugs Market - Global Forecast 2026-2032- Product Image
New

Intravenous Iron Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454933
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The intravenous iron drugs market is evolving rapidly, shaped by continuous advancements in drug formulations, regulatory changes, and shifting healthcare delivery models. Senior decision-makers must navigate this transformation to ensure supply chain stability, strategic procurement, and enhanced patient pathways.

Market Snapshot: Intravenous Iron Drugs Market Overview

The Intravenous Iron Drugs Market is projected to grow from USD 3.47 billion in 2025 to USD 3.82 billion in 2026, with continued expansion expected at a CAGR of 9.94%, approaching USD 6.75 billion by 2032. This market growth is driven by rising demand in oncology, nephrology, obstetrics, and ambulatory care, coupled with technological innovation and a focus on patient-centered infusion protocols. The sector is also experiencing greater integration of digital tools, reshaping clinical efficiency and operational throughput.

Scope & Segmentation

  • Drug Formulation Types: Ferric carboxymaltose, ferumoxytol, iron dextran, iron isomaltoside, and iron sucrose—each offering unique characteristics in dosing schedules, administration requirements, and patient suitability.
  • Therapeutic Indications: Chronic kidney disease, cancer-associated anemia, pregnancy-related anemia, and various forms of iron deficiency anemia not confined to cancer or renal diseases.
  • Care Settings: Dialysis centers, oncology and specialty clinics, hospitals, and ambulatory infusion centers are primary drivers of adoption and distinct operational models.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies influence both inventory management practices and patient access across care locations.
  • Patient Demographics: Adult, geriatric, and pediatric populations represent varying clinical needs and monitoring regimens, influencing drug selection and site of care.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific, illustrating distinct infrastructure, reimbursement landscapes, and procurement strategies.
  • Technological Drivers: Digital health solutions, such as platforms for electronic prescribing, infusion scheduling, patient monitoring, and automated supply chain management, are strengthening efficiency and regulatory compliance.

Key Takeaways

  • Providers prioritize therapies that deliver rapid iron repletion while minimizing patient visits, supporting workflow efficiency in both acute and chronic care environments.
  • Resilient manufacturing and adaptable supply chains are fundamental in reducing exposure to rising input costs and market uncertainties resulting from global policy changes.
  • Drug differentiation by molecular structure and ease of administration significantly impacts procurement strategies and formulary inclusion in major hospital systems.
  • Digital workflow integration supports consistent adherence and enhances throughput within infusion suites, aligning with evolving patient care models.
  • Regional procurement models and healthcare infrastructure variations create disparities in distribution, highlighting the importance of tailored access strategies to strengthen market position.
  • Payer scrutiny regarding cost-effectiveness and reimbursement is intensifying the collaboration between care sites and pharmaceutical suppliers to demonstrate value.

Tariff Impact on the Intravenous Iron Drugs Market

New U.S. tariff policies have increased supply chain complexity and driven up the landed costs of intravenous iron therapies. In response, procurement teams are renegotiating contracts, evaluating alternative suppliers, and prioritizing domestic manufacturing options to ensure a stable supply chain. Health systems and group purchasing organizations are focusing on longer-term supplier relationships and clear service commitments to guarantee care continuity and manage budget predictability.

Methodology & Data Sources

This report synthesizes insights from peer-reviewed clinical literature, regulatory filings, payer documents, and supply chain disclosures, supplemented by interviews with clinicians, pharmacists, and procurement leads. Combining quantitative and qualitative data ensures comprehensive, actionable guidance that reflects realities in diverse regions and care settings.

Why This Report Matters

  • Empowers executive and procurement teams to benchmark internal strategies against market evolution in clinical adoption, procurement policy, and regulatory frameworks across the intravenous iron drugs market.
  • Clarifies key segments for targeted product development, optimized contracting, and risk mitigation amid changing care models and international trade dynamics.
  • Provides specific recommendations for integrating clinical workflows and digital tools to enhance efficiency and resilience in both established and emerging markets.

Conclusion

As innovation, operational resilience, and robust supply chains converge, stakeholders in intravenous iron therapies must act decisively to capitalize on emerging opportunities, build strong partnerships, and sustain competitive positioning worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Intravenous Iron Drugs Market, by Drug Type
8.1. Ferric Carboxymaltose
8.2. Ferumoxytol
8.3. Iron Dextran
8.4. Iron Isomaltoside
8.5. Iron Sucrose
9. Intravenous Iron Drugs Market, by Indication
9.1. Cancer-Associated Anemia
9.2. Chronic Kidney Disease
9.2.1. Hemodialysis
9.2.2. Peritoneal Dialysis
9.2.3. Predialysis
9.3. Iron Deficiency Anemia
9.4. Pregnancy-Related Anemia
10. Intravenous Iron Drugs Market, by Patient Age Group
10.1. Adult
10.2. Geriatric
10.3. Pediatric
11. Intravenous Iron Drugs Market, by End User
11.1. Dialysis Centers
11.2. Hospitals
11.3. Specialty Clinics
12. Intravenous Iron Drugs Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Intravenous Iron Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Intravenous Iron Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Intravenous Iron Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Intravenous Iron Drugs Market
17. China Intravenous Iron Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AMAG Pharmaceuticals, Inc.
18.6. American Regent, Inc.
18.7. Aurobindo Pharma Limited
18.8. Cipla Limited
18.9. Dr. Reddy's Laboratories Ltd.
18.10. Fresenius SE & Co. KGaA
18.11. Hikma Pharmaceuticals PLC
18.12. Luitpold Pharmaceuticals, Inc.
18.13. Lupin Limited
18.14. Novartis AG
18.15. Pfizer Inc.
18.16. Pharmacosmos A/S
18.17. Sanofi S.A.
18.18. Teva Pharmaceutical Industries Ltd.
18.19. Vifor Pharma Ltd.
18.20. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERUMOXYTOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERUMOXYTOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERUMOXYTOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON ISOMALTOSIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON ISOMALTOSIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON ISOMALTOSIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER-ASSOCIATED ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER-ASSOCIATED ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER-ASSOCIATED ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREDIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREDIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREDIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEFICIENCY ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEFICIENCY ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEFICIENCY ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREGNANCY-RELATED ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREGNANCY-RELATED ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PREGNANCY-RELATED ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 105. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 116. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 119. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 131. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 132. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 133. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. ASEAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 138. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 140. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 141. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. GCC INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 152. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 154. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. BRICS INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 159. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 160. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 161. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 162. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. G7 INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 166. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 167. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 168. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 169. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. NATO INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 180. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 181. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 182. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2032 (USD MILLION)
TABLE 183. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Intravenous Iron Drugs market report include:
  • AMAG Pharmaceuticals, Inc.
  • American Regent, Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Luitpold Pharmaceuticals, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Pharmacosmos A/S
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Vifor Pharma Ltd.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.82 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.75 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Intravenous Iron Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Intravenous Iron Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Iron Drugs Market - Global Forecast 2026-2032 - Product Image

Iron Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Intravenous Iron Drugs Market Report 2025 - Product Image

Intravenous Iron Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Intravenous (IV) Iron Drugs - Global Strategic Business Report - Product Image

Intravenous (IV) Iron Drugs - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From

About the Intravenous Iron Market

The Intravenous Iron market is a segment of the Hematological Drugs market, which includes drugs used to treat anemia and other blood disorders. Intravenous Iron is a type of drug used to treat iron deficiency anemia, a condition in which the body does not have enough iron to produce healthy red blood cells. Intravenous Iron is administered directly into the bloodstream, allowing for a more rapid increase in iron levels than oral iron supplements. Intravenous Iron is used in a variety of settings, including hospitals, clinics, and home care. It is often prescribed to patients who are unable to take oral iron supplements due to gastrointestinal issues or who require a more rapid increase in iron levels. The Intravenous Iron market is highly competitive, with a number of companies offering products in this space. Some of the major players in the market include Vifor Pharma, Fresenius Kabi, American Regent, and B. Braun. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.